Disclosures for "Elevated Level of Oxidative DNA Damage and Impaired DNA Repair Efficiency of PBMCs from Chronic Inflammatory Demyelinating Polyneuropathy"
-
The institution of Ms. Filipek has received research support from National Centre of Science, Poland - Preludium Bis 2019/35/O/NZ5/02270.
-
Ms. Macieja has nothing to disclose.
-
Dr. Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda Pharmaceuticals. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for argenx. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for argenx. Dr. Roy has stock in Cabaletta bio. . The institution of Dr. Roy has received research support from Martin Shubik Fund for IBM at Yale University. The institution of Dr. Roy has received research support from Abcuro Pharmaceuticals. The institution of Dr. Roy has received research support from Immunovant.
-
Prof. Majsterek has nothing to disclose.
-
Tomasz Poplawski has nothing to disclose.